A biomarker is an objectively measurable biological parameter that serves as an indicator of normal biological processes, disease processes, or the response to a therapeutic intervention. In clinical trials, biomarkers are used to characterize patients, assess efficacy at an early stage, or identify safety risks.
Types of Biomarkers and Typical Applications
In practice, a distinction is made between different biomarker categories. This classification helps to establish a sound study design, endpoint strategy, and analytics.
- Diagnostic biomarkers: support disease diagnosis (e.g., specific mutations or protein markers).
- Prognostic biomarkers: predict the natural course of disease, independent of treatment.
- Predictive biomarkers: indicate the likelihood of therapeutic response and are central to personalized medicine.
- Pharmacodynamic biomarkers: demonstrate biological effects of a treatment, such as signaling pathway inhibition.
- Safety biomarkers: warn of toxicity, e.g., liver values as an indicator of drug-induced damage.
In addition, monitoring biomarkers are used to track disease progression and treatment adherence, as well as response biomarkers that serve as early signals of efficacy. In oncology programs, biomarkers are often closely linked to the development of a companion diagnostic, which increases the requirements for standardization and documentation.
Biomarkers as Endpoints, Validation, and Clinical Relevance
A common pitfall is equating biomarker changes with clinical benefit. Not every biomarker is suitable as a surrogate endpoint. A surrogate endpoint replaces a clinically meaningful endpoint (e.g., morbidity or mortality) only if the relationship is robustly established. In early clinical phases, biomarkers are frequently used exploratively to optimize dose, mechanism of action, and patient selection.
For interpretation, it is important to understand the role the biomarker plays in the clinical trial protocol: Is it primary, secondary, or exploratory? Are multiplicity issues and statistical power taken into account? Particularly with many exploratory biomarkers, clear hypotheses are needed, along with a transparent approach to controlling error probabilities and proper documentation in the data management plan.
When biomarkers serve as inclusion/exclusion criteria, cut-offs must be justified in a comprehensible manner. In practice, cut-offs are sometimes derived from retrospective datasets; sensitivity analyses and a plan for re-validation should be included to ensure that results do not arise merely by chance in a subpopulation.
To ensure robust interpretation, potential sources of bias should be actively addressed: incomplete sample submission (selection bias), batch effects in the laboratory, or confounding due to concomitant medication and disease stage. Predefined analysis populations and sensitivity analyses help make results more robust.
Operational Implementation: Sample Chain, Data Flows, and Quality
Biomarker data are only as good as the underlying analytics. Typical requirements concern pre-analytics (sample collection, processing, storage), measurement method (e.g., immunological assays, PCR, sequencing), and evaluation. In GCP-compliant studies, processes must be documented in a traceable manner, including equipment calibration, reagent tracking, and audit trail in the electronic system.
Depending on the purpose, different levels of validation are required. For biomarkers used as inclusion criteria or primary endpoints, robust performance data (accuracy, precision, limit of detection, stability) are critical. Inter-laboratory comparisons and standardization also reduce variability. From a clinical data management perspective, biomarker variables should be integrated early into the case report form structure, including plausibility checks and a clear query process.
Operationally relevant is also the chain of custody: from sample collection at the investigational site, through transport conditions, to measurement at the central laboratory. Documentation gaps or temperature deviations can invalidate analyses and frequently lead to findings in audits. Therefore, responsibilities, shipping windows, and escalation pathways should be clearly defined in SOPs.
Significance for Clinical Trials
Biomarkers influence numerous operational and regulatory aspects: they guide patient selection, define subgroup analyses, and can shape the benefit-risk assessment. For sponsors and CROs, a clear biomarker plan is relevant to consistently plan sample logistics, central laboratory integration, data flows (electronic data capture), and statistical evaluation. If biomarkers are to become relevant for regulatory argumentation, it must be clarified early on what evidence of clinical relevance is expected and how the biomarker strategy aligns with endpoints such as overall survival or progression-free survival.
In EU contexts, data protection and sample/data use also play a role: informed consent forms should clearly cover biospecimens, genetic analyses, secondary use, and retention periods.
Frequently Asked Questions (FAQ)
What is the difference between predictive and prognostic biomarkers?
Prognostic biomarkers describe the course of disease independent of therapy, while predictive biomarkers indicate whether a specific treatment is likely to be effective. Predictive biomarkers are therefore particularly important for treatment decisions and subgroups in clinical trials.
When is a biomarker considered a surrogate endpoint?
A biomarker is considered a surrogate endpoint only if it is scientifically established that changes in the biomarker reliably reflect clinical benefit. This typically requires consistent evidence from multiple studies and a plausible biological mechanism of action.
What quality requirements apply to biomarker data in clinical trials?
Essential are controlled pre-analytics, validated measurement methods, traceable documentation, and consistent data flows. In addition, plausibility checks, query management, and an audit trail should ensure that data are accurate, complete, and traceable.
Regulatory References
- ICH E6(R3) Good Clinical Practice: Requirements for data integrity, traceability, and quality in clinical trials.
- EU Regulation 536/2014 (Clinical Trials Regulation): Requirements for clinical trials in the EU, including documentation and safety requirements.
- ICH E9 (Statistical Principles for Clinical Trials): Principles for planning and evaluation, relevant for biomarker analyses and subgroups.